Follow
Gerald J. Atkins
Gerald J. Atkins
Professor of Orthopaedic Research, COTR, University of Adelaide
Verified email at adelaide.edu.au - Homepage
Title
Cited by
Cited by
Year
Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway
AR Wijenayaka, M Kogawa, HP Lim, LF Bonewald, DM Findlay, GJ Atkins
PloS one 6 (10), e25900, 2011
5482011
Biocompatible polymer coating of titania nanotube arrays for improved drug elution and osteoblast adhesion
K Gulati, S Ramakrishnan, MS Aw, GJ Atkins, DM Findlay, D Losic
Acta biomaterialia 8 (1), 449-456, 2012
3372012
Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1α, 25-dihydroxyvitamin D3
GJ Atkins, PH Anderson, DM Findlay, KJ Welldon, C Vincent, ...
Bone 40 (6), 1517-1528, 2007
3342007
RANKL expression is related to the differentiation state of human osteoblasts
GJ Atkins, P Kostakis, B Pan, A Farrugia, S Gronthos, A Evdokiou, ...
Journal of Bone and Mineral Research 18 (6), 1088-1098, 2003
2942003
Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint
DR Haynes, TN Crotti, M Loric, GI Bain, GJ Atkins, DM Findlay
Rheumatology 40 (6), 623-630, 2001
2942001
Sclerostin is a locally acting regulator of late‐osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE‐ASARM‐dependent mechanism
GJ Atkins, PS Rowe, HP Lim, KJ Welldon, R Ormsby, AR Wijenayaka, ...
Journal of Bone and Mineral Research 26 (7), 1425-1436, 2011
2842011
Receptor activator of nuclear factor-κB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo
AN Farrugia, GJ Atkins, LB To, B Pan, N Horvath, P Kostakis, DM Findlay, ...
Cancer research 63 (17), 5438-5445, 2003
2782003
The proliferation and phenotypic expression of human osteoblasts on tantalum metal
DM Findlay, K Welldon, GJ Atkins, DW Howie, ACW Zannettino, D Bobyn
Biomaterials 25 (12), 2215-2227, 2004
2602004
Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response
GJ Atkins, KJ Welldon, P Halbout, DM Findlay
Osteoporosis International 20, 653-664, 2009
2572009
The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis
DR Haynes, TN Crotti, AE Potter, M Loric, GJ Atkins, DW Howie, ...
The Journal of Bone & Joint Surgery British Volume 83 (6), 902-911, 2001
2522001
Osteoprotegerin (OPG) is localized to the Weibel‐Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor
ACW Zannettino, CA Holding, P Diamond, GJ Atkins, P Kostakis, ...
Journal of cellular physiology 204 (2), 714-723, 2005
2342005
Osteocytes: the master cells in bone remodelling
M Prideaux, DM Findlay, GJ Atkins
Current opinion in pharmacology 28, 24-30, 2016
2332016
Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls
DR Haynes, E Barg, TN Crotti, C Holding, H Weedon, GJ Atkins, ...
Rheumatology 42 (1), 123-134, 2003
2322003
Expression of osteoclast differentiation signals by stromal elements of giant cell tumors
GJ Atkins, DR Haynes, SE Graves, A Evdokiou, S Hay, S Bouralexis, ...
Journal of Bone and Mineral Research 15 (4), 640-649, 2000
2312000
Osteocyte regulation of bone mineral: a little give and take
GJ Atkins, DM Findlay
Osteoporosis international 23, 2067-2079, 2012
2212012
Pro‐inflammatory cytokines TNF‐related weak inducer of apoptosis (TWEAK) and TNFα induce the mitogen‐activated protein kinase (MAPK)‐dependent expression of sclerostin in human …
C Vincent, DM Findlay, KJ Welldon, AR Wijenayaka, TS Zheng, ...
Journal of bone and mineral research 24 (8), 1434-1449, 2009
2052009
Osteoclastic Metabolism of 25(OH)-Vitamin D3: A Potential Mechanism for Optimization of Bone Resorption
M Kogawa, DM Findlay, PH Anderson, R Ormsby, C Vincent, HA Morris, ...
Endocrinology 151 (10), 4613-4625, 2010
2002010
Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL‐induced apoptosis
A Evdokiou, S Bouralexis, GJ Atkins, F Chai, S Hay, M Clayer, DM Findlay
International journal of cancer 99 (4), 491-504, 2002
1952002
TWEAK is a novel arthritogenic mediator
SJ Perper, B Browning, LC Burkly, S Weng, C Gao, K Giza, L Su, ...
The Journal of Immunology 177 (4), 2610-2620, 2006
1922006
Bril: a novel bone‐specific modulator of mineralization
P Moffatt, MH Gaumond, P Salois, K Sellin, MC Bessette, É Godin, ...
Journal of bone and mineral research 23 (9), 1497-1508, 2008
1862008
The system can't perform the operation now. Try again later.
Articles 1–20